[go: up one dir, main page]

TW200513531A - CCN1 compositions and methods - Google Patents

CCN1 compositions and methods

Info

Publication number
TW200513531A
TW200513531A TW093118013A TW93118013A TW200513531A TW 200513531 A TW200513531 A TW 200513531A TW 093118013 A TW093118013 A TW 093118013A TW 93118013 A TW93118013 A TW 93118013A TW 200513531 A TW200513531 A TW 200513531A
Authority
TW
Taiwan
Prior art keywords
ccn1
sequence
adhesion
compositions
methods
Prior art date
Application number
TW093118013A
Other languages
Chinese (zh)
Other versions
TWI356097B (en
Inventor
Lester F Lau
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Publication of TW200513531A publication Critical patent/TW200513531A/en
Application granted granted Critical
Publication of TWI356097B publication Critical patent/TWI356097B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The angiogenic inducer CCN1 (cysteine-rich 61, CYR61), a secreted matricellular protein of the CCN family, is a ligand of multiple integrins including α6 β1. In this study, we demonstrate that human skin fibroblasts adhere specifically to the T1 sequence (GQKCIVQTTSWSQCSKS) within domain III of CCN1, and this process is blocked by anti-a6 and anti-b1 monoclonal antibodies. Alanine substitution mutagenesis of the T1 sequence further defines the sequence TTSWSQCSKS as the critical determinant for mediating α6 β1-dependent adhesion. Soluble T1 peptide specifically inhibits fibroblast adhesion to CCN1 in a dose-dependent manner.
TW93118013A 2003-06-20 2004-06-21 Ccn1 compositions and methods TWI356097B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48016103P 2003-06-20 2003-06-20

Publications (2)

Publication Number Publication Date
TW200513531A true TW200513531A (en) 2005-04-16
TWI356097B TWI356097B (en) 2012-01-11

Family

ID=34519960

Family Applications (1)

Application Number Title Priority Date Filing Date
TW93118013A TWI356097B (en) 2003-06-20 2004-06-21 Ccn1 compositions and methods

Country Status (5)

Country Link
EP (1) EP1636251A4 (en)
CN (1) CN1835763B (en)
HK (1) HK1095743A1 (en)
TW (1) TWI356097B (en)
WO (1) WO2005040191A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022511A1 (en) 2007-08-06 2009-02-11 Corlife GbR Bioactive coating for an implantable device or bioprosthesis
AU2009209157B2 (en) 2008-01-30 2015-06-11 Asterias Biotherapeutics, Inc. Synthetic surfaces for culturing stem cell derived cardiomyocytes
JP5703028B2 (en) 2008-01-30 2015-04-15 アステリアス バイオセラピューティクス インコーポレイテッド Synthetic surface for culturing stem cell-derived oligodendrocyte progenitor cells
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
US20110183418A1 (en) * 2009-07-29 2011-07-28 Arthur Winston Martin Peptide-Polymer Cell Culture Articles and Methods of Making
CN104749371B (en) * 2013-12-30 2016-09-28 神州细胞工程有限公司 People's nephroblastoma overepressed gene encoding proteins enzyme linked immunological kit
CN105396136B (en) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）Application in treatment skin injury and atrophoderma relevant disease
CN107312864B (en) * 2017-08-14 2021-03-05 中国医学科学院北京协和医院 WISP3 gene mutation for PPD auxiliary diagnosis and application thereof
CN107505462A (en) * 2017-08-14 2017-12-22 上海市同仁医院 A kind of Cyr61 protein detection kits and its application method
CN112118857A (en) * 2018-05-17 2020-12-22 株式会社橄榄生物科技 Pharmaceutical composition for preventing or treating retinal diseases comprising CCN5 as an active ingredient
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN114324526B (en) * 2021-12-27 2023-06-27 青岛农业大学 Biosensor for detecting prostate specific antigen in human serum and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071954A (en) * 1992-11-20 1993-05-12 沈阳市胸科医院 Method for pretreatment of specimen used in examining tubercle bacillus by polyase chain reaction
DE69727558T2 (en) * 1996-03-15 2004-12-16 Munin Corporation, Chicago Human CYR61, a signaling molecule of the extracellular matrix
IL150885A0 (en) * 2000-01-31 2003-02-12 Munin Corp Cyr61 compositions and methods

Also Published As

Publication number Publication date
CN1835763A (en) 2006-09-20
HK1095743A1 (en) 2007-05-18
WO2005040191A2 (en) 2005-05-06
WO2005040191A3 (en) 2006-03-23
EP1636251A4 (en) 2009-07-29
TWI356097B (en) 2012-01-11
EP1636251A2 (en) 2006-03-22
CN1835763B (en) 2011-04-20

Similar Documents

Publication Publication Date Title
TW200513531A (en) CCN1 compositions and methods
DK1347730T4 (en) Recombinant anti-CD30 antibodies and uses thereof
RS52484B (en) Antibodies to cd40
PT1171143E (en) PHARMACEUTICAL OR COSMETIC OR NUTRACEUTICAL COMPOSITION FOR A PRIMARY EXTRACT OF TREMOCH AND PHARMACEUTICAL OR NUTRACEUTIC COMPOSITION UNDERSTANDING THE ABOVE EXTRACT
TR200202253T2 (en) Recombinant IL-18 antagonists useful in the treatment of IL-18 induced disorders
MX2007013626A (en) Antibodies directed against amyloid-beta peptide and methods using same.
DE69925024D1 (en) USE OF EPH RECEPTOR ANTAGONISTS AND AGONISTS FOR THE TREATMENT OF VASCULAR DISEASES
ES2162637T3 (en) STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEX.
NO20016007D0 (en) Recombinant anti-CD40 antibody and uses thereof
HUP0204074A2 (en) Humanized antibodies that sequester abetha peptide
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
EA200602015A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
WO2002047715A3 (en) Compositions of peptide crystals
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
MY147019A (en) Anti-alpha v beta 6 antibodies
EP1469810A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO AMYLOID-BETA PEPTIDE
BRPI0413489A (en) cd20 binding polypeptide compositions
HRP20210436T1 (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
AU3576597A (en) Endoderm, cardiac and neural inducing factors
JP2020537649A5 (en)
EA032189B9 (en) Isolated human monoclonal antibodies against tissue factor pathway inhibitor (tfpi) and pharmaceutical composition comprising same
AU2021205415A8 (en) Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists
EA200201138A1 (en) PEPTIDE, MODELING RECEPTOR THROMBOPOETHINE
CR6528A (en) METHOD FOR INHIBITING THE AGGREGATION OF AMILOID PROTEINS AND FORMATION OF AMILOID DEPOSIT IMAGES
GB0016189D0 (en) Cosmetic composition

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees